TD Cowen Forecasts Strong Price Appreciation for Humana (NYSE:HUM) Stock

Humana (NYSE:HUM) had its price objective increased by TD Cowen from $261.00 to $268.00 in a report published on Monday,Benzinga reports. The firm currently has a hold rating on the insurance provider’s stock.

A number of other research analysts also recently commented on the company. Leerink Partners downgraded Humana from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $400.00 to $250.00 in a research report on Wednesday, October 2nd. Truist Financial decreased their price objective on Humana from $400.00 to $260.00 and set a “hold” rating on the stock in a research report on Friday, October 11th. KeyCorp initiated coverage on Humana in a report on Friday, October 11th. They issued a “sector weight” rating for the company. Jefferies Financial Group lowered Humana from a “buy” rating to a “hold” rating and decreased their price target for the company from $519.00 to $253.00 in a report on Monday, October 7th. Finally, Royal Bank of Canada dropped their target price on Humana from $400.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Twenty research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Humana currently has a consensus rating of “Hold” and a consensus target price of $315.86.

Humana Stock Performance

NYSE HUM opened at $287.76 on Monday. The business has a 50-day moving average price of $291.98 and a 200-day moving average price of $333.24. The firm has a market cap of $34.65 billion, a price-to-earnings ratio of 25.56, a price-to-earnings-growth ratio of 1.98 and a beta of 0.52. Humana has a twelve month low of $213.31 and a twelve month high of $527.18. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. The firm had revenue of $29.30 billion during the quarter, compared to analyst estimates of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. As a group, equities research analysts predict that Humana will post 16.15 EPS for the current fiscal year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a $0.885 dividend. The ex-dividend date is Tuesday, December 31st. This represents a $3.54 annualized dividend and a yield of 1.23%. Humana’s dividend payout ratio is currently 31.36%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of HUM. Mendota Financial Group LLC grew its holdings in Humana by 9.2% during the 2nd quarter. Mendota Financial Group LLC now owns 319 shares of the insurance provider’s stock valued at $119,000 after purchasing an additional 27 shares in the last quarter. Capital Advisors Ltd. LLC increased its holdings in Humana by 17.0% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 213 shares of the insurance provider’s stock worth $80,000 after purchasing an additional 31 shares during the last quarter. CarsonAllaria Wealth Management Ltd. raised its position in shares of Humana by 111.4% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after purchasing an additional 39 shares in the last quarter. Harbour Investments Inc. boosted its stake in shares of Humana by 10.5% during the 2nd quarter. Harbour Investments Inc. now owns 432 shares of the insurance provider’s stock valued at $161,000 after buying an additional 41 shares during the last quarter. Finally, Baader Bank Aktiengesellschaft increased its stake in shares of Humana by 1.0% in the second quarter. Baader Bank Aktiengesellschaft now owns 4,421 shares of the insurance provider’s stock worth $1,649,000 after buying an additional 42 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.